spacer
home > > winter 2019 > exploring growth strategies for smaller cros
PUBLICATIONS


Exploring Growth Strategies for Smaller CROs

Over the last several decades, clinical trials have increased in size, cost, complexity, and duration, resulting in sponsors becoming increasingly reliant on the outsourcing services of CROs. The number of countries involved in Phase 3 clinical studies doubled between 2005-15, and the number of investigative sites increased by 63%. Simultaneously, the mean number of patients declined by 18%, adding complexity to the study start-up process and putting greater pressure on CROs to deliver (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Zac Beda is Director and co-founder at Upsilon Global. As Director of Europe and APAC, he is responsible for supporting business development and bid-defence activities for their small/ mid-sized CRO partners, helping them to win more clinical studies, upscale their operations, and cost-effectively launch clinical programmes in new countries and new regions. Their model is built on a global network of clinical, regulatory, and quality affairs consultants, built over three decades of experience within the healthcare industry. Upsilon Global are currently operational in over 50 countries across six continents.
spacer
Zac Beda
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics and ClexBio Introduce CYTRIX Microfluidic Hydrogel Kit

Cambridge, UK and Oslo, Norway, 7 June 2021: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and ClexBio, a pioneer in solutions for tissue engineering and single-cell techniques, today announced the launch of the biocompatible CYTRIX Microfluidic Hydrogel Kit.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement